Editorial
|
|
|
The effects of the Agency for Drug Reconciliation will be felt worldwide
|
|
|
New Products
|
|
|
Why risk adding bismuth?
|
|
|
|
|
|
|
Bone marrow fibrosis: theory versus practice
|
|
|
Adverse Effects
|
|
|
Bleeding, seepage
|
|
|
|
|
Reviews
|
|
|
Part 1 - Initial treatment: usually a low-molecular-weight heparin
|
|
|
|
Outlook
|
|
|
Sluggish progress, timid measures to protect patients
|
|
|
|
|
|
|
|
Patients and healthcare professionals should reassess ongoing treatments
|
|
|
|